Pituitary metastases: presentation and outcomes from a pituitary center over the last decade.
Cancer
Diabetes insipidus
Hypopituitarism
Malignancy
Metastases
Metastatic
Pituitary
Journal
Pituitary
ISSN: 1573-7403
Titre abrégé: Pituitary
Pays: United States
ID NLM: 9814578
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
pubmed:
20
3
2020
medline:
2
2
2021
entrez:
20
3
2020
Statut:
ppublish
Résumé
Highlight and characterize manifestations, diagnostic/management approaches and outcomes in a contemporary cohort of patients with pituitary metastases (PM) from a large European pituitary center-over 10 years. Retrospective review of PM cases between 1/2009 and 12/2018. Clinical, laboratory, imaging data at PM detection and during follow-up were analysed. 18 cases were identified (14 females; median age at diagnosis 61.5 years). Most common primary malignancies were lung (39%) and breast (32%). Most frequent presenting manifestation was visual dysfunction (50%). Gonadotrophin, ACTH, TSH deficiency were diagnosed in 85%, 67%, 46% of cases, respectively; diabetes insipidus (DI) was present in 17%. 33% of cases were detected during investigation for symptoms unrelated to PM. PM management included radiotherapy (44%), transsphenoidal surgery (17%), transsphenoidal surgery and radiotherapy (6%) or monitoring only (33%). One-year survival was 49% with median survival from PM detection 11 months (range 2-47). In our contemporary series, clinical presentation of PM has evolved; we found increased prevalence of anterior hypopituitarism, decreased rates of DI and longer survival compared with older literature. Increased availability of diagnostic imaging, improvements in screening and recognition of pituitary disease and longer survival of patients with metastatic cancer may be contributing factors.
Identifiants
pubmed: 32189207
doi: 10.1007/s11102-020-01034-2
pii: 10.1007/s11102-020-01034-2
pmc: PMC7181548
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
258-265Références
Endocr Connect. 2018 Aug 23;:
pubmed: 30139817
Neuro Oncol. 2011 Aug;13(8):916-22
pubmed: 21665918
World Neurosurg. 2017 Oct;106:254-265
pubmed: 28673886
Pituitary. 2016 Feb;19(1):11-8
pubmed: 26238305
Presse Med. 1999 Oct 2;28(29):1567-71
pubmed: 10544705
Cancer. 1975 Jul;36(1):216-20
pubmed: 1203849
Pituitary. 2015 Feb;18(1):159-68
pubmed: 24445565
J Clin Endocrinol Metab. 2004 Feb;89(2):574-80
pubmed: 14764764
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3379-3388
pubmed: 30892659
Oncotarget. 2017 Feb 16;8(33):55544-55549
pubmed: 28903440
Pituitary. 2014 Dec;17(6):575-87
pubmed: 24337713
J Clin Endocrinol Metab. 2011 Jun;96(6):1633-41
pubmed: 21470998
Pituitary. 2018 Oct;21(5):463-473
pubmed: 29974330
World Neurosurg. 2013 Feb;79(2):327-30
pubmed: 22480977
J Neurosurg. 2006 Dec;105 Suppl:37-42
pubmed: 18503328
Neurol Med Chir (Tokyo). 2004 Mar;44(3):112-6; discussion 117
pubmed: 15095963
Surg Neurol. 2009 Sep;72(3):248-55; discussion 255-6
pubmed: 18786712
J Neurooncol. 2017 Mar;132(1):127-133
pubmed: 28070828
J Clin Endocrinol Metab. 1987 Sep;65(3):469-74
pubmed: 3624409